Sobi shares gain momentum as the company reports successful Phase 3 REDUCE-2 trial results, confirming the efficacy and safety of its investigational gout therapy, pozdeutinurad.
Sobi has achieved a significant clinical milestone with its investigational drug pozdeutinurad, as Phase 3 REDUCE-2 data confirmed durable serum urate reductions over a 12-month period. As a highly selective URAT1 inhibitor, this once-daily treatment represents a potential breakthrough in the company's pipeline, strengthening its therapeutic portfolio. The positive trial results provide a clear path forward for regulatory submissions and potential commercialization of the asset.
It is an investigational, once-daily, highly selective URAT1 inhibitor developed by Sobi.
The study demonstrated statistically significant and durable serum urate reductions in patients over a 12-month period.
Swedish Orphan Biovitrum (Sobi) announced positive Phase 3 data for its investigational gout treatment, pozdeutinurad. The study met its primary endpoints, demonstrating statistically significant and durable serum urate reductions over a 12-month period for the once-daily URAT1 inhibitor.
Pozdeutinurad is an investigational, once-daily, highly selective URAT1 inhibitor developed by Sobi for the treatment of gout.
The trial demonstrated statistically significant and durable serum urate reductions in patients over a 12-month treatment period.